Phenylketonuria (PKU) is a rare autosomal recessive condition caused by mutations in the phenylalanine-4-hydroxylase (PAH) gene. This gene is involved in the production of the PAH enzyme. Since this enzyme is necessary for the breakdown of the amino acid phenylalanine, its deficiency leads to an accumulation of phenylalanine in the blood. If untreated, the toxic effects of phenylalanine can lead to severe and permanent intellectual impairment. Other symptoms of untreated PKU include neurological issues, eczematous rash, motor deficits, delayed development, and behavioral and psychiatric problems.
PKU Awareness Day, which was on December 3, reminds us of the importance of promoting patient care and support, driving research, and accelerating the timeline for a cure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze